Sun Pharmaceuticals and Ranbaxy Laboratories have sold seven of their formulations to Emcure Pharmaceuticals to comply with an order from the Competition Commission of India (CCI).
According to Khaitan & Co, legal advisers to Sun Pharma, this is the first divestment of assets in India following a CCI order.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
